Major Licensing Deals and M&A
Executive Summary - June 9 to June 16, 2026
The June 9-16 window was M&A-led and US/EU-centric. The marquee transaction was GSK's agreement to acquire Nuvalent for an equity value of about $10.6B (announced June 9), via a $124.00-per-share all-cash tender offer at roughly a 40% premium. The deal adds two late-stage, highly selective non-small-cell lung cancer (NSCLC) assets - the ROS1 inhibitor zidesamtinib and the ALK inhibitor neladalkib - and is GSK's third major deal of 2026.
The cross-border (China-out) licensing engine paused again in-window: no major out-licensing deal was announced between June 9 and June 16, the second consecutive M&A-led week. A smaller bolt-on - PharmaEssentia's $36.5M acquisition of its Canadian partner FORUS Therapeutics (announced June 11) - rounded out the week. As always, BD professionals should anchor to near-term cash and de-risking; this week's deals were late-stage US/EU acquisitions rather than early-stage portfolio licensing.
M&A Transactions - June 9 to June 16, 2026
| Date | Acquirer | Target | Deal Value | Strategic Rationale |
|---|---|---|---|---|
| Jun 9, 2026 (announced) | GSK | Nuvalent (US) | ~$10.6B (GBP 8.0B) equity value; $124.00/share cash | All-cash tender offer at roughly a 40% premium to the prior close; expected to close in 2H 2026 subject to tender and regulatory conditions. Adds two late-stage, highly selective NSCLC assets - zidesamtinib (NVL-520, a ROS1 inhibitor with an FDA target action date of Sep 18, 2026) and neladalkib (NVL-655, an ALK inhibitor with a target action date of Nov 27, 2026) - plus NVL-330 (HER2, Phase 1). GSK's third major deal of 2026; deepens its oncology and precision-NSCLC franchise. |
| Jun 11, 2026 (announced) | PharmaEssentia | FORUS Therapeutics (Canada) | US$36.5M | Brings in-house its existing Canadian commercialization partner for BESREMi (ropeginterferon alfa-2b-njft), expanding PharmaEssentia's North American commercial footprint in myeloproliferative neoplasms. |
No major licensing or partnering transaction, including China-out, was announced in the June 9-16 window. Section 1 this week therefore centers on M&A.
Weekly Takeaways
- M&A over licensing, again: GSK-Nuvalent (~$10.6B) dominated the week and no cross-border out-licensing deal landed in-window - the second straight M&A-led week.
- Precision NSCLC keeps commanding premiums. GSK paid roughly a 40% premium for two best-in-class-positioned, highly selective ROS1 and ALK inhibitors, underscoring continued buyer appetite for de-risked, late-stage targeted oncology.
- The China-out engine is paused, not stalled. No major out-license landed in-window; prior large China-to-West pacts continue moving toward their H2 2026 closes, and China-origin oncology (bispecifics, ADCs) remains the most-traded category year to date.
- Late-stage assets price on near-term cash. GSK's all-cash structure for two near-approval assets contrasts sharply with the low single-digit upfront-to-total ratios typical of early-stage China-out portfolio licensing.
- What to watch next week: post-EHA partnering interest in GPRC5D bispecifics and B-cell-malignancy combinations, upcoming FDA actions (Nuvalent's zidesamtinib PDUFA Sep 18), and continued mid-cap consolidation into the 2025-2030 patent cliff.
Global Biomedicine Highlights
Clinical Readouts & Regulatory - June 9 to June 16, 2026
June 11-14, 2026 - J&J MonumenTAL-3 Phase 3: Talquetamab + Daratumumab Combinations Extend PFS in Relapsed/Refractory Multiple Myeloma (EHA 2026)
At EHA 2026 in Stockholm, Johnson & Johnson presented MonumenTAL-3, a Phase 3 study adding its GPRC5D bispecific antibody talquetamab (Talvey) to daratumumab (Darzalex Faspro), with or without pomalidomide, in relapsed or refractory multiple myeloma after at least one prior line of therapy. The talquetamab-containing regimens reduced the risk of disease progression or death by up to 72% versus standard daratumumab + pomalidomide + dexamethasone (DPd), with a 24-month progression-free survival rate of up to 81.3% for the talquetamab combinations versus 51.2% for the standard-of-care arm.
BD Implication: GPRC5D-directed bispecific T-cell engagers continue to move into earlier treatment lines, reinforcing bispecifics as a top oncology partnering theme - directly relevant to the wave of China-origin bispecific and ADC assets seeking Western development and commercialization partners.
June 11-14, 2026 - Incyte frontMIND Phase 3: Tafasitamab + Lenalidomide + R-CHOP Prolongs PFS in First-Line DLBCL (EHA 2026 Plenary)
Incyte presented pivotal Phase 3 frontMIND data in a Plenary session at EHA 2026, showing that adding tafasitamab (an anti-CD19 antibody) and lenalidomide to R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival in previously untreated diffuse large B-cell lymphoma (DLBCL), reducing the risk of disease progression or death by 25% versus R-CHOP alone.
BD Implication: A positive frontline DLBCL readout validates CD19-targeted antibody combinations in a large first-line indication and supports continued dealmaking in B-cell malignancy assets, including antibody and cell-therapy programs originating in China.
June 13, 2026 - Agios RISE UP Phase 3: Oral Mitapivat Cuts Transfusion Burden in Sickle Cell Disease (EHA 2026 Plenary)
Agios presented 52-week double-blind data from the global Phase 3 RISE UP trial of mitapivat, an oral pyruvate kinase activator, in patients aged 16 and older with sickle cell disease. Mitapivat delivered a 41.1% relative reduction in the proportion of patients requiring blood transfusions (23.9% with mitapivat vs. 40.6% with placebo) and a 55.9% relative reduction in the average number of red blood cell units transfused per patient; the hemoglobin-response primary endpoint had been met at topline in November 2025, and safety was consistent with prior trials.
BD Implication: An oral, disease-modifying mechanism that de-risks a historically difficult hemoglobinopathy category is relevant to China-origin small-molecule and oral platforms seeking Western partners, and reinforces dosing convenience as a competitive axis in rare hematology.
Calendar note: also at EHA on June 12, Disc Medicine presented updated RALLY-MF Phase 2 data for DISC-0974 (anti-hemojuvelin) in myelofibrosis with anemia - over 55% of non-transfusion-dependent patients achieved a major hemoglobin response, and 64% (low-burden) and 50% (high-burden) of transfusion-dependent patients achieved transfusion independence - alongside HELIOS open-label extension data for bitopertin in erythropoietic protoporphyria. Other readouts reviewed this week dated outside the June 9-16 window and were omitted accordingly.
Job Postings
Executive and senior-level openings across C-suite, BD&L, R&D leadership, manufacturing, and medical affairs - spanning both U.S. and China-based employers - are tracked on the dedicated Job Board. BD&L talent searches frequently pair with the buyer and fund mandates on the Opportunity Board below.
View the Job BoardBD&L Opportunity Board
Active In-Licensing Mandates (New This Week + Standing)
Several new buyer in-licensing mandates were registered this week - spanning three hematology disease areas (polycythemia vera, von Willebrand disease, warm autoimmune hemolytic anemia), a 16-target wish list weighted toward myeloproliferative and hematology biology, and small-molecule weight loss via energy expenditure - and are listed first below. The standing mandates from prior weeks continue beneath them. All are US/EU buyer or fund mandates with ex-China or global rights preferred unless noted, and new assets matching any mandate can be routed via the BD inbox at any time. Two new service and capital offerings (an ADC CDMO and an ADC investment mandate) appear in Section 4.4.
Hematology Diseases - Polycythemia Vera, Von Willebrand Disease, Warm AIHA
US/EU companies are in-licensing programs across three hematology indications: polycythemia vera (PV), von Willebrand disease (VWD), and warm autoimmune hemolytic anemia (warm AIHA). Large molecules, small molecules, siRNA, and peptides are all acceptable; preclinical stage is acceptable. Ex-China / global rights preferred.
Target-Interest Mandates - 16 New Targets
US/EU companies are in-licensing programs against the following targets (mechanism in parentheses where specified); preclinical stage is acceptable: CHRM4 inhibitor; COX / 5-LOX inhibitor; FcRn inhibitor; IFN-gamma inhibitor; JAK2 V617F mutant-selective inhibitor; LNK inhibitor; AKT1 inhibitor; APJ antagonist; BMP9 recombinant protein (mimic endogenous BMP9); CALR mutant-selective inhibitor; matriptase-2 inhibitor; plasminogen inhibitor; protein S inhibitor; SF3B1 splicing modulator; TIE2 inhibitor; and TPO receptor / MPL inhibitor. Ex-China / global rights preferred.
Small-Molecule Weight Loss via Energy Expenditure
US/EU companies are in-licensing small-molecule weight-loss programs, oral formulations preferred. They are not seeking traditional appetite-suppression mechanisms; rather, they want weight loss achieved by boosting energy metabolism or energy expenditure. Preclinical stage is acceptable. Ex-China / global rights preferred.
Rare & Special Movement Disorders, Motor Neuron Disease, Rare Epilepsy
US/EU companies are in-licensing novel, potentially disease-modifying therapies for rare and special movement disorders, motor neuron disease, and rare epilepsy. Projects at any stage are welcome and modality is open. Ex-China / global rights preferred.
TRAIL Agonist - Target Interest
US/EU companies are in-licensing TRAIL-agonist programs. Assets from preclinical candidate (PCC) stage through Phase II can be considered; indication flexible. Ex-China / global rights preferred.
Oligonucleotide & Small Nucleic Acid Programs (Fund Mandate)
A well-established US/EU fund is seeking siRNA, antisense oligonucleotide, and small nucleic acid programs. No restriction on disease area; preclinical assets are acceptable. Ex-China / global rights preferred.
Cardiovascular & Kidney Disease - Multi-Modality
US/EU companies are in-licensing cardiovascular and kidney disease programs across modalities - small molecules, large molecules, siRNA, peptides, and antisense oligonucleotides. Preclinical assets are acceptable. Ex-China / global rights preferred.
KRAS G12V - Target-Specific (Oncology)
US/EU buyer seeking to in-license a KRAS G12V-targeted oncology program. Target-specific mandate open to small molecule or biologic; asset must be IND-cleared or later. Ex-China / global rights preferred.
AL Amyloidosis - Disease-Area Mandate
US/EU buyer disease-area mandate for AL amyloidosis. Small molecule or biologic; preclinical candidate (PCC) stage or later. Mechanism open.
ANCA-Associated Vasculitis (GPA, MPA, EGPA)
US/EU buyer disease-area mandate for ANCA-associated vasculitis across GPA, MPA, and EGPA. Small molecule or biologic; PCC stage or later. Mechanism open.
Anemia of Chronic Kidney Disease
US/EU buyer disease-area mandate for anemia of chronic kidney disease. Small molecule or biologic; PCC stage or later. Mechanism open.
Anemia of Inflammatory Bowel Disease
US/EU buyer disease-area mandate for anemia of inflammatory bowel disease. Small molecule or biologic; PCC stage or later. Mechanism open.
CCR3 Antagonist - Target Interest
US/EU buyer target-interest mandate for CCR3 antagonist programs. Preclinical-stage assets acceptable; indication flexible. Ex-China / global rights preferred.
JAG1 Agonist - Target Interest
US/EU buyer target-interest mandate for JAG1 (Jagged-1) agonist programs. Preclinical-stage assets acceptable; indication flexible.
ENTPD1 / CD39 Antagonist - Target Interest
US/EU buyer target-interest mandate for ENTPD1 (CD39) antagonist programs. Preclinical-stage assets acceptable; immuno-oncology focus.
Geographic-Arbitrage: Chinese Phase I/IIa Assets
Fund invests in Chinese-originated Phase I or IIa assets, re-runs / extends clinical development in EU/US (Western data is more readily accepted by MNCs), then out-licenses or sells to MNCs.
Newco Formation around Phase III Programs
Large European/American funds building purpose-built Newcos around Phase III clinical-stage programs in Oncology, Autoimmune, and CNS. Asset contributable or out-licensable into a fund-backed Newco structure.
Sourcing Cross-Reference - What to Flag into Biolink
For readers with assets or intros that match the mandates above, the following cross-reference summarizes what Biolink can route directly to the relevant buyer or fund.
| Buyer Mandate | What to Source / Flag to Biolink |
|---|---|
| Hematology Diseases (PV, VWD, warm AIHA) | Programs for polycythemia vera, von Willebrand disease, or warm autoimmune hemolytic anemia; large or small molecule, siRNA, or peptide; preclinical acceptable; ex-China / global rights. |
| Target-Interest - 16 New Targets | Programs against CHRM4, COX/5-LOX, FcRn, IFN-gamma, JAK2 V617F (mutant-selective), LNK, AKT1, APJ, BMP9 (recombinant), CALR (mutant-selective), matriptase-2, plasminogen, protein S, SF3B1, TIE2, or TPO-R/MPL; preclinical acceptable. |
| Small-Molecule Weight Loss (energy expenditure) | Oral-preferred small molecules that drive weight loss via energy metabolism / expenditure (not appetite suppression); preclinical acceptable. |
| Rare/Special Movement Disorders, MND, Rare Epilepsy | Disease-modifying programs for rare/special movement disorders, motor neuron disease, or rare epilepsy; any stage; modality open. |
| TRAIL Agonist | TRAIL-agonist programs from PCC through Phase II; indication flexible. |
| siRNA / ASO / Small Nucleic Acid (fund) | Oligonucleotide and small-nucleic-acid programs - siRNA, antisense, small nucleic acids; any disease area; preclinical acceptable. |
| Cardiovascular & Kidney Disease | CV and renal programs - small molecule, large molecule, siRNA, peptide, or antisense; preclinical acceptable. |
| KRAS G12V (Oncology) | KRAS G12V-targeted programs, small molecule or biologic, IND-cleared or later; ex-China / global rights. |
| AL Amyloidosis | Programs for AL amyloidosis at PCC stage or later; small molecule or biologic; mechanism open. |
| ANCA-Associated Vasculitis | Programs addressing GPA, MPA, or EGPA at PCC stage or later; small molecule or biologic. |
| Anemia of CKD | Programs for anemia of chronic kidney disease at PCC stage or later; small molecule or biologic. |
| Anemia of IBD | Programs for anemia of inflammatory bowel disease at PCC stage or later; small molecule or biologic. |
| CCR3 Antagonist | CCR3 antagonist programs; preclinical acceptable; indication flexible. |
| JAG1 Agonist | JAG1 (Jagged-1) agonist programs; preclinical acceptable; indication flexible. |
| ENTPD1 / CD39 Antagonist | ENTPD1 (CD39) antagonist programs; preclinical acceptable; immuno-oncology focus. |
| Fund - China Phase I/IIa geographic-arbitrage | Chinese sponsor with a clean Phase I or IIa readout, open to a Western development plan; fund leads EU/US clinical work and downstream MNC out-license. |
| Fund - Newco around Phase III asset | Late-stage (Ph III) programs in Oncology, Autoimmune, or CNS where the originator is open to a fund-backed Newco. |
Featured License-Out
A China-based biotech is seeking global partners for a first-in-class (FIC) immunotherapy platform targeting autoimmune diseases. The platform is built on a proprietary antigen-specific tolerance technology designed to modulate immune response without systemic immunosuppression - a mechanism that, if validated, would directly address the central limitation of currently marketed biologics in this space.
| Attribute | Detail |
|---|---|
| Opportunity Type | License-Out - global partnership sought |
| Originator | China-based biotech (fully integrated; R&D, clinical, manufacturing, global supply chain) |
| Platform | First-in-class (FIC) immunotherapy platform based on proprietary antigen-specific tolerance technology. Designed to modulate the immune response without systemic immunosuppression. |
| Lead Asset - Stage | Phase II in Graves' disease (GD) |
| Additional Indications | Thyroid eye disease (TED) - Multiple sclerosis (MS) - Type 1 diabetes (T1D) |
| Clinical Readouts to Date | Safety: no severe AEs in Phase I. Efficacy: meaningful reduction in disease biomarkers. Mechanism benefit: potential for long-term disease remission via immune-tolerance induction. |
| IP Position | >150 granted patents; multiple FIC assets in the pipeline |
| Deal Type Sought | Global partnership / out-license discussions (ex-China rights negotiable) |
| Contact | BD@biorichinc.com (direct message also welcome) |
The lead asset is Phase II and the platform produces multiple FIC programs in autoimmune disease - squarely within the autoimmune mandate from Western buyers. For the geographic-arbitrage fund model, the Phase II GD program could also serve as a candidate for a Western Phase II/III re-read with fund capital, particularly given the clean Phase I safety profile.
Services & Capital - New This Week
Beyond asset licensing, two service and capital offerings were registered this week. These are not drug-licensing deals and are listed here rather than on the Licensing Opportunities page.
ADC CDMO - Services in Exchange for Equity
An ADC-focused contract development and manufacturing organization (CDMO) is offering its services in exchange for equity, supporting ADC companies that need development and manufacturing capacity. ADC companies with such needs are welcome to make contact.
ADC Investment Mandate - Chinese ADC Developers
An investor is looking to invest in Chinese ADC (antibody-drug conjugate) drug-development companies. Each investment is USD 2-3M, with a preference for ADC projects that are close to entering the CMC stage.
Contact & Submissions
- To submit assets matching any mandate above: BD@biorichinc.com (include modality, stage, last clinical readout, and territory availability).
- Browse the full, filterable opportunity set - including out-licensing assets - on the Licensing Opportunities page.
- Role cross-reference - see Section 3 (Job Postings) for BD&L professionals available for hire (VP BD, licensing counsel).
BioLink Weekly - Section 4, BD&L Opportunity Board. Prepared June 16, 2026. Buyer and fund mandates are summarized from direct briefings; specific terms available upon NDA. Deal terms and clinical figures elsewhere in this issue are drawn from company press releases and named reputable sources; unverifiable items were omitted.
BioLink Weekly is published by BioRich International, Princeton NJ.
lisa.fan@biorichinc.com